Page 64 - Read Online

Page 12 of 14 Webster et al. J Cancer Metastasis Treat 2020;6:8 I http://dx.doi.org/10.20517/2394-4722.2019.38

O’Connor ML, Hansen AR, Kircher S, Jim HSL, Dicker AP, Janda M, Ala-leppilampi K, Bingham CO III,
Feliciano J, Henry NL, Steffen McLouth LE, Cella D

Availability of data and materials
Not applicable.

Financial support and sponsorship
Laurie E. Steffen McLouth was supported by NCI R25 CA122061 (PI: Avis); Adam P. Dicker received
additional support from the National Cancer Institute, the Prostate Cancer Research Program (Dept. of
Defense), the American Society of Radiation Oncology, the American Society of Clinical Oncology, NRG
Oncology, and the Prostate Cancer Foundation; Josephine Feliciano received additional support from
Bristol Myers Squibb and Astra Zeneca.

Conflicts of interest
Heather S.L. Jim is a consultant for RedHill BioPharma Ltd and Janssen Scientific Affairs; Aaron R.
Hansen is a consultant for Merck (compensated) and GSK (compensated), and has received grant/research
support from (Clinical Trials for institution) from Genentech/Roche, Merck, GSK, Bristol-Myers Squibb,
Novartis, Boston Biomedical, Boehringer-Ingelheim, AstraZeneca, Medimmune, Janssen, Karyopharm,
and Macrogenics; David Cella is the President and owner of FACIT.org; Kimberly A. Webster is an
owner of FACIT.org; Clifton O. Bingham III is a consultant to Bristol Myers Squibb, Regeneron/Sanofi,
and Genentech/Roche, and has received grant support from Bristol Myers Squibb; Adam P. Dicker is an
advisor for Roche, EMD Serono, Celldex, Janssen, Cybrexa, Self Care Catalysts, Oncohost, ThirdBridge,
and Noxopharm (compensated), and to Google LaunchPad Accelerator, Dreamit Ventures, and Evolution
Road (uncompensated). He has also provided expert testimony for Intellectual property (Wilson Soncini);
Josephine Feliciano is a consultant to Astra Zeneca, Genentech, Eli Lilly, Pfizer, and Merck. Sheetal Kircher,
Monica Janda, Laurie E. Steffen McLouth, N. Lynn Henry, Mary O’Connor and Kari Ala-leppilampi declare
no relevant interests, financial or otherwise.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor
mutational burden. N Engl J Med 2018;378:2093-104.
2. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med
2015;372:2509-20.
3. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-
cell lung cancer. N Engl J Med 2016;375:1823-33.
4. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, et al. Management of immune-related adverse events in patients treated
with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol 2018;36:1714-68.
5. Ventola CL. Cancer immunotherapy, part 2: efficacy, safety, and other clinical considerations. P T 2017;42:452-63.
6. Carretero-Gonzalez A, Lora D, Ghanem I, Zugazagoitia J, Castellano D, et al. Analysis of response rate with ANTI PD1/PD-L1
monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. Oncotarget 2018;9:8706-15.
7. Temel JS, Gainor JF, Sullivan RJ, Greer JA. Keeping expectations in check with immune checkpoint inhibitors. J Clin Oncol
2018;36:1654-7.